
Recursion Pharmaceuticals ($RXRX) announced positive Phase 1b/2 results for its AI-developed drug REC-4881, showing rapid and durable reductions in polyp burden. This news, coupled with NVIDIA ($NVDA) being an investor and Cathie Wood's recent buying, makes $RXRX a potentially attractive opportunity, especially given its 40% short interest.

By beaniemaxi
Crypto native since the early days. Went all in on DeFi summer. Then tripled down on NFTs. VC @gmcapital_. No paid promos. Not financial advice. I talk my book.